Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2012. The document serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the Deferred Annual Bonus Plan (DABP) post-tax awards for the 2011 bonus year.
Key Financial Metrics
The filing does not report consolidated revenue, profit, cash flow, margins, debt, or liquidity figures for the company. It focuses exclusively on executive compensation mechanics and specific transaction details for one executive.
- Transaction Date: March 12, 2012
- ADS Acquisition Price: US$44.63
- Executive Participant: Ms. D. Connelly
- Co-Investment Shares Acquired: 1,240 ADSs
Material Changes and Performance Targets
The filing details the performance conditions for the Matching Award component of the DABP, which spans the period from January 1, 2012, to December 31, 2014. Vesting is contingent on four equally weighted measures:
- Total Shareholder Return (TSR): Relative performance against a comparator group of 10 global pharmaceutical companies. Vesting ranges from 0% (below median) to 100% (upper quartile).
- Adjusted Free Cash Flow: Specific thresholds are set for vesting:
- 25% vesting at £17.30 billion
- 50% vesting at £17.84 billion
- 75% vesting at £19.62 billion
- 100% vesting at £20.52 billion
- R&D New Product Performance: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 122% of the threshold.
- Business Diversification: Targets are undisclosed due to commercial sensitivity. Vesting ranges from 25% at threshold to 100% at 114% of the threshold.
Guidance, Outlook, and Risks
The filing does not provide general corporate guidance or outlook. It notes that specific targets for R&D and business diversification will be disclosed at the end of the performance period. A key risk highlighted is that any element of the conditional award that does not meet the performance threshold will lapse entirely.
Investor Verification Checklist
- Verify the final vesting outcomes for the 2012-2014 performance period once disclosed.
- Confirm the actual Adjusted Free Cash Flow achieved by GSK against the £17.30 billion to £20.52 billion thresholds.
- Review the final TSR ranking of GSK against the specified comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi).
- Monitor future disclosures for the specific R&D and business diversification targets that were withheld in this filing.